WAYNE, PA — Teleflex Incorporated (NYSE: TFX) presented significant clinical findings at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas. The data from two randomized controlled trials (RCTs) underline the UroLift™ System’s superiority in treating benign prostatic hyperplasia (BPH), showing clear advantages over Rezūm and tamsulosin in early patient satisfaction, symptom relief, and sexual function outcomes.
The UroLift™ System, a leading minimally invasive treatment for BPH in the U.S., demonstrated faster and more effective results compared to Rezūm in the CLEAR RCT. Men treated with the UroLift™ System reported significantly higher satisfaction levels at two weeks and one month post-treatment. They also experienced shorter catheterization times, better symptom relief, and improved sexual function during early recovery.
Further data from the IMPACT RCT showed that UroLift™ significantly outperformed tamsulosin on symptom improvement at three months. Patients who underwent the UroLift™ procedure reported better sexual function outcomes and overall satisfaction. Notably, 70% of patients initially randomized to the medication group opted to switch to the UroLift™ therapy.
“These studies underscore our commitment to evidence-based innovation. The UroLift™ System continues to stand out as a patient-centered therapy offering meaningful improvements in symptoms and quality of life,” said Claus Roehrborn, MD, professor of urology at UT Southwestern Medical Center and primary investigator on the studies. “With more than 14 years of BPH research behind us, we’re giving clinicians and patients the critical data to support evidence-based shared decisions.”
Real-world findings from the American Urological Association Quality Registry (AQUA) further confirmed the UroLift™ System’s rapid symptom improvement at three months, compared to the modest or negligible effects observed with drug treatments.
Additionally, Teleflex shared breakthrough data on the safety of stabilized hyaluronic acid (sHA) rectal spacers, an innovation aiding prostate cancer treatment. Research highlighted the spacer’s low risk of rectal wall infiltration and reversibility, with no severe complications, such as ulcers or fistulas.
“These findings reaffirm the safety profile of stabilized hyaluronic acid as a rectal spacer and highlight its reversibility as a distinct clinical advantage,” stated Michelle Svatos, director of Barrigel™ rectal spacer product development and research.
With these findings, Teleflex reinforces the UroLift™ System’s position as a preferred BPH treatment and showcases its commitment to advancing patient outcomes through innovation. The data is expected to drive shared, evidence-based decision-making while improving the quality of care for BPH and prostate cancer patients.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.